Wilmington Savings Fund Society FSB Lowers Stake in Eli Lilly and Company $LLY

Wilmington Savings Fund Society FSB reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 26.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 27,904 shares of the company’s stock after selling 9,800 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Eli Lilly and Company were worth $21,291,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. 10Elms LLP lifted its stake in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the last quarter. Bridgewater Advisors Inc. boosted its stake in Eli Lilly and Company by 0.3% in the third quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock worth $3,018,000 after buying an additional 11 shares in the last quarter. Manske Wealth Management grew its position in Eli Lilly and Company by 2.5% during the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after acquiring an additional 11 shares during the last quarter. Guardian Partners Inc. lifted its holdings in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after acquiring an additional 12 shares during the last quarter. Finally, FSA Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. FSA Wealth Management LLC now owns 309 shares of the company’s stock valued at $236,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Wolfe Research boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,313.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,221.44.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive pediatric Phase 3 data for EBGLYSS (lebrikizumab) expands Lilly’s immunology franchise and supports non‑GLP revenue diversification — a constructive pipeline read for long‑term growth. Lilly Pediatric EBGLYSS Data
• Positive Sentiment: Local expansion: Pennsylvania officials and the Parkland school district are discussing incentives and tax breaks for Lilly’s proposed manufacturing campus — supports capacity for higher GLP‑1 demand and shows state support for operational scaling. LVEDC Meeting Lauds Lilly Parkland Considers Tax Breaks
• Positive Sentiment: Sales momentum remains strong: industry coverage notes Lilly has leapfrogged on obesity sales (tirzepatide franchise), underpinning the company’s revenue leadership in GLP‑1s. That supports near‑term cash flow and valuation anchors. Biospace: Lilly Leapfrogs on Obesity Sales
• Neutral Sentiment: Some Wall Street firms remain bullish (high price targets and platform/market‑access initiatives like Employer Connect), creating mixed analyst views versus the downgrade risk. Wall Street Firms Turn Bullish
• Negative Sentiment: HSBC downgraded LLY to “reduce” (lowered PT to $850), citing pricing pressure, rising competition and what it calls “priced‑to‑perfection” obesity expectations — the downgrade is the main catalyst for the sharp intraday drop. Why LLY Shares Are Plunging
• Negative Sentiment: Competing oral GLP‑1/obesity pill data and news (Structure Therapeutics, Novo Nordisk developments) raise the risk of faster pricing pressure and market share erosion for injectables and future orals. Investors are re‑pricing probability of continued outsized growth. Bloomberg: Structure Pill Rivals Lilly Structure Therapeutics Pops
• Negative Sentiment: Regulatory/market‑access uncertainty for oral obesity treatments and headlines about FDA decisions have amplified near‑term volatility and prompted profit‑taking after a long run‑up. 247wallst: FDA Oral Pill Decision Weighs on Shares

Eli Lilly and Company Stock Down 5.9%

Shares of Eli Lilly and Company stock opened at $931.03 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a market cap of $879.65 billion, a P/E ratio of 40.57, a PEG ratio of 1.15 and a beta of 0.40. The company’s fifty day simple moving average is $1,033.54 and its two-hundred day simple moving average is $955.52.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.